TWiV 903: COVID-19 clinical update #116 with Dr. Daniel Griffin

This Week in Virology - Un podcast de Vincent Racaniello

In COVID-19 clinical update #115, Dr. Griffin discusses croup association with infection surge, rhinovirus co-circulation in children, shedding following vaccination, high vaccine efficacy in children 6 mo-5 yr, vaccine protection for hospitalized patients, convalescent plasma as post-exposure prophylaxis, real-world effectiveness of PAXLOVID, effectiveness of PAXLOVID in reducing hospitalization, infection rebound after PAXLOVID, relapse of symptomatic infection after PAXLOVID, remdesivir and bebtelovimab fact sheets for providers, guidelines on usage of anticoagulation drugs, long covid symptoms after vaccination, excess mortality in MA, infection sequelae and immunity, and post infection conditions among adults. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Croup association with infection surge (PIDS) Rhinovirus co-circulation in children (Science Direct) Infection shedding following vaccination (MedRxiV) High vaccine efficacy in children 6 months to 5 years (Pfizer) Protection of vaccine against hospitalized patients (IDSA) Convalescent plasma as post-exposure prophylaxis (IDSA) Real-world effectiveness of PAXLOVID in Hong-Kong (MedRxiV) Effectiveness of PAXLOVID in reducing hospitalization (The Lancet) Infection rebound after PAXLOVID (CDC) Relapse of symptomatic infection after PAXLOVID (Research Square) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Guidelines on usage of anticoagulation drugs (ASH) Long covid symptoms after vaccination (BMJ) Excess morality in Massachusetts (JAMA) Infection sequelae and immunity (Annals of Internal Medicine) Post infection conditions among adults (CDC) Contribute to FIMRC fundraiser at PWB Dr. Griffin’s treatment guide (pdf) Letters read on TWiV 903 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]

Visit the podcast's native language site